**Cytokine diagnosis of pleural tuberculosis: will it stand the test of time?**

Marc Tebruegge1,2,3,4 and Paul Elkington1\*

1NIHR Biomedical Research Centre,Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK. 2Department of Paediatric Infectious Diseases & Immunology, Evelina London Children’s Hospital, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK. 3Great Ormond Street Institute of Child Health, University College London, London, UK. 4Department of Paediatrics, University of Melbourne, Melbourne, Australia.

**\* Address for correspondence:**

Professor Paul T Elkington

Clinical and Experimental Sciences

University of Southampton, Southampton SO16 1YD

Tel: 00 44 23 8120 6149

E-mail: p.elkington@soton.ac.uk

Word count: 1113

The need for better diagnostics for tuberculosis (TB) has been repeated so frequently that there is a danger of message fatigue. However, the unfortunate return of TB as the number one cause of death due to an infectious disease must surely serve as a further call to action for researchers, clinicians and funders to redouble our efforts 1. The fundamental issues with TB diagnosis deserve repeating: standard diagnosis of pulmonary TB relies primarily on sputum smear tests, which have limited sensitivity and specificity, and have not significantly changed for over 100 years 2. Recent data show that staining for acid-fast bacilli remains the most commonly used diagnostic method globally 3. The development of interferon-gamma release assays (IGRAs) and molecular amplification tests such as Xpert MTB/RIF assays has improved the landscape somewhat, but both are critically limited by cost and the need for extensive infrastructure. In addition, IGRAs do not distinguish latent from active TB, have limited robustness, and perform worse in children than in adults 4-6. Recent data suggest that the roll-out and scale-up of the Xpert MTB/RIF assays in resource-limited settings has been far slower than anticipated 7. Importantly, molecular assays require relatively high numbers of bacilli to achieve adequate sensitivity. The diagnosis of extra-pulmonary TB is often more challenging than pulmonary TB, frequently with low bacterial loads in difficult to access locations. Therefore, the majority of TB diagnosis still relies on smear and culture results of specimens taken by the least invasive route, and considerable clinical acumen is often required to determine the likelihood of TB in the face of negative culture results. Data from a recent global survey suggest that microbiologists and clinicians managing patients with TB require better diagnostic tests for TB to be developed, highlighting the significant limitations of existing tests 3.

On this background, the study of Wang *et al* published in this edition of *Thorax* provides a welcome addition to the literature on TB diagnosis 8. The group built on their previous observations that interleukin-27 (IL-27) may be a novel diagnostic marker of pleural TB, and also studied interferon-γ (IFN-γ) and adenosine deaminase (ADA) in patients with tuberculous and non-tuberculous pleural effusions. They then studied IL-27 in a second cohort before proceeding to a meta-analysis. They report excellent test performance with a specified cut-off value, finding IL-27 more accurate than ADA and equivalent to IFN-γ. Combination of IL-27 and ADA improved specificity, but at the expense of sensitivity. The authors conclude that in high TB prevalence settings, IL-27 could be used as a rule-in test to diagnose pleural TB, and in low prevalence settings as a rule-out test. These findings potentially warrant further development.

The diagnosis of pleural TB has historically been difficult, in part due to the pathophysiology of the disease. Advanced pulmonary TB is characterised by tissue destruction, hypoxia and cavitation 9, with high bacterial loads within the cavity wall 10, whereas pleural TB has a relatively low bacterial load with extensive fluid collection 11. Consequently, pleural fluid culture is positive in fewer than 50% of cases 12. Previous gold standard diagnosis has centred on pleural biopsies, as histology showing granulomas on the pleural surface has greater specificity and sensitivity than pleural fluid microscopy and culture. However, pleural biopsy with Abrams needle has become an uncommon investigation, in part due the low incidence of TB in high-resource countries, and many clinicians with access to thoracic surgery proceed directly to video-assisted thoracoscopic surgery to obtain diagnostic tissue. ADA, an enzyme used as a marker of T cell activation, showed initial promise as a novel diagnostic for pleural TB 13, but is not widely used in routine clinical practice in many countries.

The study by Wang *et al* inevitably raises further questions. Firstly, the correct cut-off for IL-27 needs to be determined, as their meta-analysis included studies with concentrations ranging from 391 to 1007 ng/ml as diagnostic of pleural TB. Secondly, the utility of IL-27 will depend on the pre-test probability, which itself results from the local TB epidemiology, and therefore the findings from high-incidence settings may not translate to lower incidence settings. Thirdly, the difference between IL-27 and IFN-γ is not so striking that is it clear which should go forward as the optimal diagnostic test. Since IFN-γ is the readout of IGRAs, this may drive more rapid development of next generation IFN-γ assays to accurately measure concentrations, which would provide an advantage in investigating this analyte further. Finally, cytokine testing is not routinely performed even in major clinical service laboratories, unlike other analytes such as C-reactive protein and albumin. Analysis of IFN-γ from QuantiFERON assays is usually batched for weekly analysis in most centres, as the number of tests does not justify daily analytical runs, and so how an occasional assay for IL-27 would be performed in laboratories in high-income settings is uncertain. In low-income settings, it seems even more unlikely that such tests will become routinely available without major advances in assay technology.

A further limitation of the approach described by Wang *et al* is that it requires thoracentesis, which is invasive compared with assays based on blood, saliva or urine. Unfortunately, Wang *et al* found that IL-27 concentrations in serum did not differ between TB patients and the control patients with malignant or parapneumonic effusion in their study. Also, their approach would only be useful in a small proportion of TB patients, as patients with isolated pleural TB constitute only 5-10% of the total TB caseload in most settings 14. Therefore, how IL-27 as a novel diagnostic marker will move forward remains an open question. As an emerging diagnostic analyte, it faces precisely the same challenges as other putative biomarkers of TB, such as mass spectrometry or aptamer identified biomarkers 15 16, matrix degradation products 17, or *M. tuberculosis*-specific cytokine responses in blood 18 that have shown promise in individual studies but need development and further validation.

Ultimately, the goal for the TB diagnostic field must remain to achieve the criteria previously outlined for an ideal TB test: available at the point-of-care, cheap, stable in heat and humidity, requiring minimal training, no electricity and no reagents to be added 19. This represents a very high bar, and to date has remained elusive, but such an assay will be critical in accelerating the diagnosis of TB in high incidence settings and therefore preventing transmission and containing the ongoing pandemic 20. The study by Wang *et al* is a step in the right direction, adding to the literature on potential emerging diagnostic biomarkers. The challenge is now to confirm the findings in further cohorts and develop novel analytical approaches that can move diagnostics based on emerging biomarkers from the research laboratory to the clinic.

**References**

1. Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. *Lancet Infect Dis* 2016;16(4):e34-46. doi: 10.1016/S1473-3099(16)00070-0

2. Dheda K, Barry CE, 3rd, Maartens G. Tuberculosis. *Lancet* 2016;387(10024):1211-26. doi: 10.1016/S0140-6736(15)00151-8

3. Amicosante M, D’Ambrosio L, Munoz M, et al. Current use and acceptability of active TB diagnostics - a worldwide survey study. *Brazil J Pulmonology* 2017;43:1-13. doi: <http://dx.doi.org/10.1590/S1806-37562017000000219>

4. Edwards A, Gao Y, Allan RN, et al. Corticosteroids and infliximab impair the performance of interferon-gamma release assays used for diagnosis of latent tuberculosis. *Thorax* 2017 doi: 10.1136/thoraxjnl-2016-209397

5. Jarvis J, Gao Y, de Graaf H, et al. Environmental temperature impacts on the performance of QuantiFERON-TB Gold In-Tube assays. *J Infect* 2015;71(2):276-80. doi: 10.1016/j.jinf.2015.04.004

6. Tebruegge M, Ritz N, Curtis N, et al. Diagnostic Tests for Childhood Tuberculosis: Past Imperfect, Present Tense and Future Perfect? *The Pediatric infectious disease journal* 2015;34(9):1014-9. doi: 10.1097/INF.0000000000000796

7. Cazabon D, Suresh A, Oghor C, et al. Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress? *Eur Respir J* 2017;50(2) doi: 10.1183/13993003.00918-2017

8. Wang W, Zhou Q, Zhai K, et al. Diagnostic accuracy of interleukin 27 for tuberculous pleural effusion: two prospective studies and one meta-analysis. *Thorax* 2017;In press

9. Belton M, Brilha S, Manavaki R, et al. Hypoxia and tissue destruction in pulmonary TB. *Thorax* 2016;71(12):1145-53. doi: 10.1136/thoraxjnl-2015-207402

10. Yoder MA, Lamichhane G, Bishai WR. Cavitary pulmonary tuberculosis: The Holey Grail of disease transmission. *Current Sci* 2004;86(10):74-81.

11. Frieden TR, Sterling TR, Munsiff SS, et al. Tuberculosis. *Lancet* 2003;362(9387):887-99.

12. Ferrer J. Pleural tuberculosis. *Eur Respir J* 1997;10(4):942-7.

13. Valdes L, Alvarez D, San Jose E, et al. Value of adenosine deaminase in the diagnosis of tuberculous pleural effusions in young patients in a region of high prevalence of tuberculosis. *Thorax* 1995;50(6):600-3.

14. Peto HM, Pratt RH, Harrington TA, et al. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. *Clin Infect Dis* 2009;49(9):1350-7. doi: 10.1086/605559

15. Achkar JM, Cortes L, Croteau P, et al. Host Protein Biomarkers Identify Active Tuberculosis in HIV Uninfected and Co-infected Individuals. *EBioMedicine* 2015;2(9):1160-8. doi: 10.1016/j.ebiom.2015.07.039

16. De Groote MA, Sterling DG, Hraha T, et al. Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis. *J Clin Microbiol* 2017 doi: 10.1128/JCM.00467-17

17. Walker NF, Wilkinson KA, Meintjes G, et al. Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study. *Clin Infect Dis* 2017;65(1):121-32. doi: 10.1093/cid/cix231

18. Tebruegge M, Dutta B, Donath S, et al. Mycobacteria-Specific Cytokine Responses Detect Tuberculosis Infection and Distinguish Latent from Active Tuberculosis. *Am J Respir Crit Care Med* 2015;192(4):485-99. doi: 10.1164/rccm.201501-0059OC

19. McNerney R, Daley P. Towards a point-of-care test for active tuberculosis: obstacles and opportunities. *Nat Rev Microbiol* 2011;9(3):204-13. doi: 10.1038/nrmicro2521 [published Online First: 2011/02/18]

20. Elkington PT, Friedland JS. Permutations of time and place in tuberculosis. *Lancet Infect Dis* 2015;15(11):1357-60. doi: 10.1016/S1473-3099(15)00135-8